Clinical Deep Dives

Med School Audio - Medical Knowledge Reimagined & Learning Made Memorable.
  • 5.0 (1)
  • Medicine
  • Updated daily

Clinical Deep Dives is a Medlock Holmes podcast for clinicians and learners who want understanding, not just information. Using classic medical and surgical texts as a guide and the generative power of AI, each episode explores ideas with curiosity and clarity, designed for learning on the move and knowledge that actually sticks. drmanaankarray.substack.com

  1. 4 hr ago

    PSYCH 093: Phenomenology of Schizophrenia

    Medlock Holmes enters an enormous archive filled with thousands of witness statements. Some describe voices no one else can hear. Others speak of thoughts being inserted, removed, or broadcast beyond the boundaries of the mind. Some accounts are crowded with elaborate conspiracies. Others contain only a few sparse words, long silences, diminished expression, and a life gradually emptied of purpose. Every file is different. Yet all have been placed beneath the same heading: Schizophrenia. Holmes immediately recognises the central challenge. There is no definitive laboratory test that confirms the diagnosis. No single hallucination, delusion, movement, or pattern of speech belongs exclusively to schizophrenia. The disorder remains defined through phenomenology: the disciplined study of what a person experiences, how those experiences are expressed, and how they change across time. The investigation begins with history. Kraepelin organised the illness around course and deterioration, describing dementia praecox as a disruption of intellect, emotion, and volition. Bleuler shifted attention towards the fragmentation of psychological functions and his Four As: disturbed associations, autism, abnormal affect, and ambivalence. Schneider later attempted to improve diagnostic reliability through first-rank symptoms such as thought insertion, thought withdrawal, thought broadcasting, passivity experiences, and voices commenting or conversing. Each investigator illuminated part of the landscape. None captured the whole country. Modern diagnostic systems therefore rely not upon one pathognomonic clue, but upon patterns of symptoms, duration, functional change, and exclusions. Hallucinations, delusions, disorganised speech, abnormal behaviour, and negative symptoms must be interpreted alongside mood episodes, substance exposure, medical illness, developmental history, and longitudinal course. Holmes then divides the archive into several great chambers. The first contains psychotic symptoms. Hallucinations may arise in any sensory modality, although auditory voices are most common. Delusions range from persecution and reference to grandiosity, passivity, religious meaning, and altered ownership of thought. Yet neither hallucinations nor delusions are unique to schizophrenia. Their diagnostic significance lies in their severity, persistence, context, and relationship with the rest of the syndrome. The second chamber contains negative symptoms. Here the clues are quieter and more easily missed: avolition, anhedonia, asociality, diminished emotional expression, and alogia. These symptoms often predict disability more powerfully than hallucinations or delusions. Holmes also learns to distinguish primary negative symptoms from those caused by depression, medication, institutional deprivation, fear, or distracting psychosis. What appears to be absence of motivation may have several entirely different causes. The third chamber contains disorganisation. Speech becomes tangential, vague, derailed, or incoherent. Behaviour loses its internal structure. Gestures become purposeless, clothing inappropriate, affect incongruent, and ordinary action strangely fragmented. Thought disorder is not a disorder of what someone believes, but of how ideas are linked and communicated. Around these principal chambers lie others that psychiatry has sometimes neglected: depression, anxiety, trauma, obsessive-compulsive symptoms, agitation, hostility, suicidality, impaired insight, and cognitive difficulty. These are not decorative details. They shape risk, distress, engagement, functioning, and treatment. Holmes realises that phenomenology requires more than checking boxes. A voice may be threatening, comforting, commanding, or companionable. A delusion may be fleeting or systematised, terrifying or grandiose. Silence may reflect alogia, depression, fear, sedation, or distrust. The same outward sign may conceal entirely different inner experiences. The skilled clinician must therefore listen beyond the label. By the end of the investigation, Holmes understands that schizophrenia is not a single portrait but a gallery of shifting constellations. Its symptoms cluster into recognisable dimensions, yet each person’s pattern remains unique. The diagnosis begins with observation. Understanding begins with curiosity. Key Takeaways * Schizophrenia remains a phenomenologically defined disorder without a diagnostic biomarker. * Diagnosis depends upon symptom patterns, duration, functional change, longitudinal course, and exclusion of alternative causes. * Kraepelin emphasised course and deterioration; Bleuler focused on fragmentation of psychic functions; Schneider described first-rank symptoms. * No hallucination, delusion, or other single symptom is pathognomonic of schizophrenia. * DSM-5-TR requires at least two core symptoms, with at least one being delusions, hallucinations, or disorganised speech. * DSM-5-TR requires six months of disturbance, including at least one month of active symptoms. * Traditional subtypes of schizophrenia were removed because they lacked stability and predictive value. * Psychotic symptoms include hallucinations and delusions; they should not be used as a synonym for all positive symptoms. * Auditory hallucinations are most common, but multimodal hallucinations occur frequently. * Delusions differ in content, conviction, preoccupation, distress, and behavioural impact. * Negative symptoms include avolition, anhedonia, asociality, diminished emotional expression, and alogia. * Negative symptoms are major predictors of disability and long-term functioning. * Secondary negative symptoms may result from depression, psychosis, medication, environmental deprivation, or extrapyramidal effects. * Disorganisation includes formal thought disorder, inappropriate affect, abnormal behaviour, and some motor phenomena. * Depression, anxiety, trauma, obsessive-compulsive symptoms, agitation, substance use, and cognitive impairment commonly complicate schizophrenia. * Suicide risk is particularly elevated early in illness, during relapse, around admission or discharge, and when depression or emerging insight is present. * Violence risk should never be inferred from diagnosis alone; substance use, victimisation, threat beliefs, impulsivity, non-adherence, and previous behaviour matter more. * Insight is multidimensional and may vary across awareness of illness, symptoms, treatment need, and consequences. * Rating scales support consistency, but they must never replace the patient’s narrative. * Good phenomenology asks not only whether a symptom exists, but what it means within that person’s life. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe

  2. 1 day ago

    PSYCH 092: Schizophrenia

    Schizophrenia is one of the most misunderstood disorders in medicine. It is not simply a condition of hallucinations and delusions; it is a disorder that disrupts perception, cognition, motivation, emotion, and the ability to connect with the world. For centuries it was viewed as madness, then as degeneration, later as a dopamine disorder, and now increasingly as a disorder of brain circuits, neurodevelopment, and dysfunctional neural networks. In this opening chapter of the schizophrenia series, Medlock Holmes begins the investigation by asking a deceptively simple question: What actually goes wrong inside a brain that loses its grip on reality? We explore the historical evolution of schizophrenia-from ancient descriptions of prophets and visionaries to modern neuroscience-and examine why the illness remains one of psychiatry’s greatest scientific challenges. The episode introduces psychosis not as a single disease but as a complex symptom that may arise from multiple underlying biological mechanisms. The chapter also explains why modern psychiatry is gradually moving beyond rigid diagnostic labels towards studying dimensions of dysfunction such as psychosis, cognition, negative symptoms, and affective disturbance. Rather than one illness with one cause, schizophrenia may represent several overlapping diseases sharing common clinical features. Finally, we examine why medication alone is never enough. The strongest evidence now shows that early comprehensive intervention-including psychological therapies, cognitive remediation, family education, community support, and pharmacological treatment-offers the greatest opportunity for long-term recovery. This episode serves as the gateway to the entire schizophrenia section, introducing the detective framework that will guide the chapters ahead as we investigate genetics, neurodevelopment, imaging, cognition, treatment, recovery, and the biology of psychosis itself. Key Takeaways • Schizophrenia is far more than hallucinations. It affects multiple domains including perception, cognition, motivation, emotion, social functioning, and independent living. • Psychosis remains one of neuroscience’s greatest mysteries. Understanding the neural mechanisms of psychosis is central to discovering better treatments and biologically based disease classifications. • Dopamine explains treatment-but probably not the whole disease. Current antipsychotics reduce dopamine signalling effectively, yet schizophrenia likely involves multiple interacting neural circuits extending well beyond dopamine. • Modern research is shifting from diagnoses to dimensions. Instead of asking “What diagnosis does this patient have?”, researchers increasingly ask which domains-psychosis, cognition, negative symptoms or mood dysfunction-are disrupted. • Schizophrenia is biologically heterogeneous. Patients sharing the same diagnosis may have very different underlying disease mechanisms. • Basic neuroscience is essential. Understanding memory, synaptic plasticity, neural circuitry and cortical communication is increasingly necessary for understanding schizophrenia. • Comprehensive care outperforms medication alone. The best outcomes occur when antipsychotic medication is combined with psychological therapy, cognitive remediation, family intervention, behavioural treatment, and community support. • Early intervention changes trajectories. The RAISE model demonstrates that coordinated early treatment during first-episode psychosis significantly improves long-term outcomes. • The future lies in personalised psychiatry. As biological mechanisms become clearer, schizophrenia may eventually be subdivided into distinct brain diseases with targeted treatments rather than one broad syndrome. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe

  3. 2 days ago

    PSYCH 091: Anabolic-Androgenic Steroid-Related Disorders

    A famous bodybuilder walks into Medlock Holmes’ consulting room. He is physically magnificent. Broad shoulders. Sculpted chest. Powerful arms. Yet Holmes notices something else. The man cannot stop looking at his reflection. Every polished surface becomes another mirror. Every missed gym session feels catastrophic. Every slight reduction in muscle size feels like losing part of himself. Holmes quickly realises that this is not simply a story about muscles. It is a story about identity. Most people think anabolic-androgenic steroids (AAS) are drugs used by elite athletes chasing Olympic medals. Holmes discovers the opposite. Today, most users are ordinary men seeking a more muscular appearance rather than sporting success. The average age of first use is approximately 23 years, much later than most other illicit substances, and use is overwhelmingly confined to males. Holmes begins by separating two commonly confused substances. The drugs used by bodybuilders are anabolic-androgenic steroids, synthetic derivatives of testosterone designed to increase muscle growth while also producing masculinising effects. These are entirely different from corticosteroids such as prednisolone, which reduce inflammation and have virtually no muscle-building properties. Confusing these two families of steroids remains remarkably common among both patients and clinicians. The detective then asks a more interesting question. If testosterone is a natural hormone, why does it become dangerous? The answer lies in dosage. Medical testosterone replacement simply restores normal physiological levels. Illicit users often consume 10 to 100 times therapeutic doses, frequently combining several different steroids simultaneously (”stacking”) to achieve enormous supraphysiological androgen concentrations. The result is extraordinary muscle growth. But Holmes knows that biology never grants gifts without demanding payment. As the investigation progresses, Holmes uncovers a fascinating paradox. The body becomes stronger. The brain becomes less stable. Most users experience little psychiatric disturbance. However, a vulnerable minority develop profound psychological changes. Some become unusually energetic. Need less sleep. Feel invincible. Become impulsive. Spend recklessly. Display intense irritability. Others develop frank mania or even psychosis with grandiose or paranoid delusions. The risk increases substantially with higher steroid doses, particularly above the equivalent of 1,000 mg of testosterone per week. Then comes the opposite problem. When the steroids stop, testosterone production collapses. The hypothalamic-pituitary-testicular (HPT) axis has been suppressed by months of external hormones. Instead of euphoria comes exhaustion. Instead of confidence comes depression. Instead of libido comes sexual dysfunction. Some men become severely depressed during withdrawal, and a minority require antidepressants-or even electroconvulsive therapy-for prolonged episodes. Holmes soon encounters the most surprising diagnosis of all. Muscle dysmorphia. Unlike anorexia nervosa, where individuals see themselves as larger than they are, these men see themselves as too small, even when objectively extremely muscular. Every mirror lies. Every comparison hurts. Every kilogram of lost muscle feels like personal failure. This distorted body image becomes one of the strongest drivers of continued steroid use. Holmes realises the steroids are no longer building muscle. They are medicating fear. The detective next investigates dependence. Unlike cocaine or heroin, anabolic steroids produce relatively little acute intoxication. Yet dependence still develops. The textbook describes three interacting pathways. First, body-image anxiety drives repeated use because individuals fear losing muscularity. Second, endocrine withdrawal causes hypogonadism, depression, fatigue, reduced libido, and erectile dysfunction, encouraging users to restart steroids simply to feel normal again. Third, steroids themselves possess rewarding properties through actions involving dopamine, GABA, and opioid systems, producing feelings of confidence, power, and occasionally euphoria. Dependence therefore becomes far more complex than simple drug reward. It is simultaneously psychological, hormonal, and neurobiological. Holmes then turns his attention to the body. The muscles tell only half the story. Years of steroid exposure may produce: * Dilated cardiomyopathy * Accelerated coronary artery disease * Hypertension * Dyslipidaemia (↑ LDL, ↓ HDL) * Polycythaemia * Persistent hypogonadism * Infertility * Tendon rupture * Liver injury (particularly with oral 17-α-alkylated steroids) * Possible cognitive impairment associated with long-term exposure Ironically, muscles often become stronger than the tendons attached to them. Holmes notes that some tendon ruptures occur not during heavy lifting-but during ordinary daily activities. Finally, Holmes asks the question that truly matters. How do you treat someone whose identity has become chemically reinforced? The answer is not simply to stop the steroids. Recovery requires rebuilding three different systems. The distorted body image requires cognitive behavioural therapy and sometimes serotonergic antidepressants. The suppressed endocrine system often requires careful management by an endocrinologist using physiological testosterone replacement, clomiphene, human chorionic gonadotropin (HCG), and gradual restoration of the HPT axis. The dependence itself may require addiction-focused psychological treatments similar to those used in other substance use disorders. Holmes closes the case with one final observation. Muscles can be measured. Strength can be tested. But insecurity has no visible weight. Sometimes the heaviest burden carried by the strongest-looking person in the room is the belief that they are still not enough. Key Takeaways * Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone used primarily to increase muscle mass and physical appearance. * Most users are non-athletes seeking improved body image rather than sporting performance. * Typical onset of use occurs around 23 years of age, much later than most illicit substances. * AAS are distinct from corticosteroids such as prednisone. * Illicit users commonly take 10–100 times therapeutic testosterone doses through “stacking” multiple preparations. * Most users experience few psychiatric effects, but some develop hypomania, mania, psychosis, aggression, or severe irritability. * Withdrawal commonly produces hypogonadism, fatigue, depression, reduced libido, and erectile dysfunction. * Muscle dysmorphia is a major psychological driver of persistent steroid use. * Dependence develops through interacting body-image, endocrine, and reward-system mechanisms. * Long-term complications include cardiomyopathy, premature coronary artery disease, infertility, dyslipidaemia, tendon rupture, hepatic injury, and possible neurocognitive impairment. * Management requires psychological therapy, endocrine treatment, and addiction-focused interventions rather than simple detoxification. * Clinicians should actively enquire about AAS use in muscular men presenting with mood disorders, infertility, cardiovascular disease, or unexplained aggression. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe

  4. 3 days ago

    PSYCH 090: Sedative-, Hypnotic-, or Anxiolytic-Related Disorders

    Medlock Holmes is summoned to investigate a peculiar paradox. The patients arriving at his clinic are not chasing euphoria. Many have never bought drugs illegally. They are teachers, nurses, executives, retirees, and people living with chronic anxiety or insomnia. They followed medical advice. They took their medication exactly as prescribed. Yet months-or years-later, many discover something unsettling. They no longer know whether they are taking the medication because they still need it, or because their brain has quietly adapted to its presence. Holmes begins with the brain’s principal braking system: gamma-aminobutyric acid (GABA). Under normal circumstances, GABA prevents excessive neuronal firing, maintaining calm, sleep, and emotional stability. Benzodiazepines and related sedative–hypnotics do not replace GABA; instead, they amplify its inhibitory effects, making the brain less excitable and producing anxiolysis, sedation, hypnosis, muscle relaxation, and anticonvulsant activity. Initially, the treatment works beautifully. Sleep returns. Anxiety eases. Muscles relax. But the nervous system is designed to maintain equilibrium. With continuous exposure, GABA receptors adapt. Receptor sensitivity changes, glutamate activity increases, calcium channel function shifts, and neuroendocrine systems recalibrate. The brain quietly raises its internal “accelerator” to compensate for the external “brake.” Holmes realises this is the critical distinction many clinicians overlook. Physiological dependence is not the same as addiction. A patient who develops tolerance and withdrawal after months of appropriate medical treatment has experienced normal neuroadaptation-not necessarily a substance use disorder. Addiction requires behavioural changes: compulsive use, loss of control, continued use despite harm, craving, and impairment in functioning. The distinction is clinically and ethically essential. As Holmes follows the clues, he discovers why abrupt cessation can be dangerous. Without the enhanced GABA activity, the now-adapted nervous system becomes relatively hyperexcitable. Minor symptoms include anxiety, insomnia, tremor, irritability, sweating, nausea, and autonomic activation. More severe withdrawal can produce hallucinations, psychosis, delirium, hyperthermia, and generalised tonic–clonic seizures. Barbiturate withdrawal, in particular, may be fatal if untreated. Holmes then encounters another mystery. Why are benzodiazepines generally much safer than barbiturates? The answer lies within receptor pharmacology. Benzodiazepines are positive allosteric modulators: they require endogenous GABA before exerting their effects. Barbiturates, particularly at higher concentrations, can directly activate GABA receptors, producing profound respiratory depression. This explains why benzodiazepine overdose alone is often survivable, whereas barbiturate overdose commonly causes respiratory arrest. However, combining benzodiazepines with alcohol or opioids removes this safety margin and dramatically increases mortality. The final chapter of the investigation concerns recovery. Holmes rejects dramatic detoxification. Instead, he advocates patience. Successful treatment usually involves gradual tapering-often over weeks or months-allowing the nervous system to slowly recalibrate. Longer-acting benzodiazepines such as diazepam or clonazepam are sometimes substituted to produce a smoother withdrawal. Psychological therapies, especially cognitive behavioural approaches, teach patients how to manage the anxiety that originally prompted treatment, preventing medication from remaining the sole coping strategy. Holmes closes his notebook with a final reflection. Sometimes the greatest clinical challenge is not recognising addiction. It is recognising when a patient’s dependence is simply the predictable consequence of effective medicine-and helping them leave it safely without confusing treatment with failure. Key Takeaways * Sedative-, hypnotic-, and anxiolytic-related disorders primarily involve medications that enhance GABAergic neurotransmission, especially benzodiazepines. * Physiological dependence (tolerance and withdrawal) is not synonymous with substance use disorder. * Substance use disorder requires behavioural features such as impaired control, compulsive use, craving, and continued use despite harm. * Benzodiazepines act as positive allosteric modulators of the GABA-A receptor and require endogenous GABA to exert their effects. * Barbiturates have greater overdose risk because they can directly activate GABA receptors and produce significant respiratory depression. * Tolerance develops through neuroadaptive changes involving GABA receptors, glutamate pathways, calcium channels, and stress systems. * Withdrawal symptoms range from anxiety and insomnia to seizures, delirium, hallucinations, and autonomic instability. * Abrupt cessation after prolonged treatment significantly increases withdrawal risk. * Short-acting benzodiazepines generally produce earlier withdrawal than long-acting agents. * Benzodiazepine overdose alone is often relatively safe, but combining benzodiazepines with alcohol or opioids markedly increases mortality. * Flumazenil can reverse benzodiazepine overdose in selected circumstances. * Gradual tapering is the cornerstone of withdrawal management; many patients require individualised, prolonged dose reductions. * Cognitive behavioural therapy and other psychological interventions improve successful discontinuation and long-term anxiety management. * Barbiturate withdrawal is a medical emergency because of its high risk of seizures, delirium, and death. * Good prescribing balances effective symptom relief with careful monitoring, patient education, and planned discontinuation whenever appropriate. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe

  5. 4 days ago

    PSYCH 089: Opioid Use and Related Disorders: From Neuroscience to Treatment

    Medlock Holmes enters a city built around a remarkable hospital. Within its walls, suffering is eased. Pain is softened. Patients who could not move begin to breathe, walk, sleep, and recover. The medicines used here are powerful, ancient, and deeply valuable. Yet beyond the hospital gates, Holmes finds another city forming in the shadows. At first, the same medicines offer warmth, relief, and escape. Then tolerance develops. The dose that once brought comfort no longer works. The body adapts. The mind learns. The streets begin to reorganise around a single need: obtain the opioid, avoid withdrawal, and return to relief. Holmes follows the trail from prescription tablets to heroin, from heroin to fentanyl, from private pain to public health crisis. He discovers that opioid use disorder is not simply a problem of pleasure-seeking. It is a chronic relapsing-remitting brain disorder involving reward, motivation, memory, stress, pain, attachment, and survival. The neurobiology is central. Opioids act primarily through mu-opioid receptors, producing analgesia, euphoria, sedation, respiratory depression, and gastrointestinal effects. With repeated use, neural circuits adapt. Dopamine reward pathways are altered, stress systems become sensitised, and withdrawal becomes a powerful driver of continued use. Holmes recognises withdrawal as the body’s alarm system in reverse. Anxiety, sweating, yawning, diarrhoea, muscle aches, insomnia, rhinorrhoea, piloerection, and craving emerge when opioid signalling falls. The person may no longer be using to feel high, but to feel briefly normal. The greatest danger is overdose. Respiratory depression can silently turn sleep into coma. Fentanyl and other synthetic opioids make the margin between intoxication and death frighteningly narrow. Naloxone becomes the emergency key that can unlock the receptor and restore breathing, but it is only the beginning of treatment. The real transformation comes through sustained care. Methadone, buprenorphine, and extended-release naltrexone each act differently at the opioid receptor, but all can reduce relapse, overdose, and mortality when properly used. Psychosocial treatment, trauma-informed care, family support, harm reduction, housing, employment, and recovery communities rebuild the wider city around the person. By the end of the investigation, Holmes sees opioid treatment not as replacing one dependence with another, but as restoring biological stability so that choice, dignity, and future can return. The mystery is not whether recovery is possible. It is why society so often withholds the very treatments that make recovery more likely. Key Takeaways * Opioids include naturally occurring, semi-synthetic, and synthetic substances such as morphine, heroin, oxycodone, methadone, buprenorphine, and fentanyl. * Opioid use disorder is a chronic relapsing-remitting condition involving brain reward, stress, memory, motivation, and control systems. * Mu-opioid receptor activation produces analgesia, euphoria, sedation, miosis, constipation, and respiratory depression. * Tolerance develops with repeated opioid exposure, often leading to escalating use. * Withdrawal may include dysphoria, anxiety, muscle aches, nausea, vomiting, diarrhoea, sweating, yawning, rhinorrhoea, piloerection, insomnia, and craving. * Opioid intoxication may present with euphoria followed by apathy, impaired judgement, drowsiness, slurred speech, miosis, and impaired attention or memory. * Opioid overdose is a medical emergency characterised by coma, respiratory depression, and often pinpoint pupils. * Naloxone reverses opioid overdose by antagonising opioid receptors and restoring ventilation. * Fentanyl and other high-potency synthetic opioids have significantly increased overdose risk. * Detoxification alone is not adequate treatment and may increase overdose risk if not followed by relapse-prevention care. * Methadone is a full opioid agonist used in maintenance treatment. * Buprenorphine is a partial opioid agonist with a ceiling effect that improves safety and can block other opioids. * Naltrexone is an opioid antagonist used after detoxification to prevent relapse. * Effective treatment combines medication, psychosocial interventions, harm reduction, medical care, and long-term recovery support. * Comorbid depression, anxiety, PTSD, antisocial traits, chronic pain, hepatitis, HIV, and polysubstance use are common and require integrated care. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe

  6. 5 days ago

    PSYCH 088: Tobacco-Related Disorders

    Medlock Holmes is summoned to investigate the greatest unsolved epidemic in modern psychiatry. Unlike the previous cases, there is no mystery about what causes the deaths. The evidence has been overwhelming for decades. Yet millions continue to use the substance. The mystery is not what tobacco does. The mystery is why humanity continues to smoke despite knowing the truth. Holmes begins where every psychiatrist must begin-with nicotine. Nicotine is one of the most powerfully addictive substances known, reaching the brain within seconds after inhalation. Each cigarette reinforces a rapid cycle of reward, relief from withdrawal, habit formation, and conditioned learning. Over years, smoking becomes far more than a behaviour-it becomes woven into identity, routines, relationships, stress management, and emotional regulation. As Holmes surveys the city, he notices something deeply troubling. The burden of tobacco is not shared equally. Psychiatric patients smoke at dramatically higher rates than the general population. Individuals with schizophrenia, mood disorders, anxiety disorders, substance use disorders, trauma histories, and adverse childhood experiences are disproportionately affected. Tobacco contributes substantially to the reduced life expectancy seen in severe mental illness-not because of psychiatric disease itself, but because of cardiovascular disease, respiratory illness, cancer, and other smoking-related conditions. Following the trail, Holmes uncovers an old misconception. For years, clinicians believed smoking helped psychiatric patients cope-that quitting might worsen their mental illness. Yet the evidence now tells a different story. Smoking cessation does not worsen long-term mental health. Instead, many patients experience improvements in mood, anxiety, quality of life, physical health, finances, and recovery from other addictions. Holmes next examines the neurobiology. Nicotine binds to nicotinic acetylcholine receptors, activating dopaminergic reward pathways within the mesolimbic system. Withdrawal emerges quickly because nicotine levels fall rapidly, producing irritability, anxiety, depressed mood, restlessness, poor concentration, insomnia, increased appetite, and intense craving. Smokers often continue smoking not to become intoxicated, but simply to avoid withdrawal. The investigation widens. Modern nicotine addiction extends far beyond cigarettes. Cigars, cigarellos, hookahs, smokeless tobacco, nicotine pouches, vaping devices, and electronic cigarettes all deliver nicotine through different routes, each carrying its own misconceptions regarding safety. Holmes carefully separates evidence from marketing, recognising that newer products often create new pathways into nicotine dependence, particularly among adolescents. Treatment, Holmes realises, is remarkably effective when approached systematically. Every patient should be asked about tobacco use. Every smoker should receive brief advice to quit. Every smoker should be offered evidence-based treatment. Behavioural therapies, motivational interviewing, relapse prevention, mindfulness approaches, quit-lines, and community supports work even better when combined with pharmacotherapy. Nicotine replacement therapy, bupropion, and varenicline substantially improve quit rates, while newer interventions such as transcranial magnetic stimulation continue to emerge. Finally, Holmes confronts the greatest irony of the case. The deadliest addictive disorder in psychiatry is also among the most treatable. The greatest tragedy is not that tobacco addiction exists. It is that clinicians sometimes fail to treat it. Key Takeaways * Tobacco use disorder is the most prevalent substance use disorder worldwide and remains the leading preventable cause of death. * Psychiatric patients smoke at far higher rates than the general population and experience disproportionate tobacco-related morbidity and mortality. * Nicotine rapidly reaches the brain, activating nicotinic acetylcholine receptors and mesolimbic dopamine reward pathways. * Dependence is maintained through both positive reinforcement and avoidance of withdrawal. * DSM-5 diagnoses Tobacco Use Disorder using the standard substance use disorder criteria, graded as mild, moderate, or severe. * Nicotine withdrawal typically includes irritability, anxiety, depressed mood, insomnia, restlessness, poor concentration, increased appetite, and craving. * Withdrawal symptoms usually peak within 1–3 days and improve over 2–3 weeks, although craving may persist for months. * Smoking cessation generally improves rather than worsens long-term mental health outcomes. * Tobacco cessation also improves recovery from many other substance use disorders. * Evidence-based psychosocial interventions include motivational interviewing, behavioural therapy, relapse prevention, mindfulness, quit-lines, and support programmes. * First-line pharmacotherapies include nicotine replacement therapy, bupropion, and varenicline. * Combining behavioural therapy with pharmacotherapy produces the highest quit rates. * Smoking induces CYP1A2 enzymes; stopping smoking increases blood concentrations of medications such as clozapine and olanzapine, requiring careful dose adjustment. * Clinicians should routinely assess smoking status using the “5 A’s”: Ask, Advise, Assess, Assist, and Arrange follow-up. * Prevention strategies include taxation, smoke-free legislation, advertising restrictions, adolescent prevention, and culturally appropriate public health interventions. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe

  7. 6 days ago

    PSYCH 087: Inhalant-Related Disorders

    Medlock Holmes is called to investigate a troubling mystery among the youngest citizens of the city. There is no dealer on the street corner. No hidden laboratory. No expensive supply chain. Instead, the clues are ordinary household objects: glue, paint thinner, spray cans, lighter fluid, petrol, correction fluid, cleaning products, and aerosol dusters. At first, the city dismisses the danger. These are not “real drugs”, people say. They are products. They are everywhere. But Holmes knows that availability can be the most dangerous disguise of all. Inhalants are volatile substances that rapidly vaporise and are inhaled for psychoactive effects. Their intoxication arrives quickly because the lungs deliver these chemicals directly into the bloodstream and then to the brain. Within minutes, a young person may experience euphoria, disinhibition, dizziness, slurred speech, unsteady gait, hallucinations, confusion, or collapse. Holmes notices that inhalant use is especially common in early adolescence. The appeal is obvious: the substances are cheap, legal, easy to conceal, and difficult to detect on routine toxicology screens. Yet the danger is profound. A single episode can cause suffocation, aspiration, burns, trauma, seizures, coma, respiratory depression, or sudden cardiac death. As Holmes follows the trail deeper, he discovers that chronic inhalant use is not merely a behavioural problem. It is a toxic assault on the body. The brain, rich in lipids and myelinated tissue, is particularly vulnerable. Long-term use can damage white matter, impair memory and executive functioning, cause cerebellar problems, produce neuropathy, and contribute to major or mild neurocognitive disorder. The investigation also reveals a familiar pattern of psychiatric complexity. Inhalant use is often associated with conduct disorder, trauma, neglect, suicidality, mood and anxiety disorders, antisocial traits, and polysubstance use. For some adolescents, experimentation stops quickly. For others, inhalants become an early warning signal of a much broader developmental pathway involving impulsivity, risk-taking, marginalisation, and future substance dependence. Treatment is difficult because the evidence base is limited. There is no simple medication that reverses inhalant use disorder. Care requires careful medical assessment, management of intoxication, attention to neurological and cognitive injury, family work, trauma-informed care, school and social support, relapse prevention, and treatment of comorbid psychiatric and substance use disorders. By the end of the case, Holmes realises that inhalants are dangerous precisely because they are ordinary. The threat does not always arrive wearing the face of crime. Sometimes it sits quietly on a shelf, waiting to be misunderstood. Key Takeaways * Inhalants are volatile substances inhaled for psychoactive effects. * Common sources include glues, paints, thinners, fuels, aerosols, cleaning products, correction fluids, and dusters. * Use is most common in younger adolescents and tends to decline with age. * Inhalant intoxication can cause euphoria, disinhibition, dizziness, slurred speech, ataxia, hallucinations, confusion, stupor, coma, or death. * A single episode may be fatal through arrhythmia, suffocation, aspiration, respiratory depression, burns, trauma, or seizures. * Routine drug screens often miss inhalant use. * Clues include chemical odour, stained clothing, solvent-soaked rags, bags, aerosol cans, or perioral/perinasal rash. * Chronic use can cause neurological injury, white matter damage, cognitive impairment, neuropathy, cerebellar signs, and neurocognitive disorder. * Inhalant use is strongly associated with conduct disorder, trauma, suicidality, polysubstance use, mood disorders, anxiety disorders, and social adversity. * Inhalant-induced psychiatric disorders may include delirium, psychosis, depressive disorder, anxiety disorder, and neurocognitive disorder. * Management of intoxication is mainly supportive, with careful monitoring of airway, breathing, circulation, consciousness, and cardiac risk. * Agitation should be managed cautiously because physical excitement may increase arrhythmia risk. * Benzodiazepines may worsen respiratory depression during acute intoxication and require caution. * Treatment of inhalant use disorder usually requires broad biopsychosocial care rather than substance-specific medication. * Prevention, early recognition, family involvement, and community support are especially important. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe

  8. 9 Aug

    PSYCH 086: Hallucinogen-Related Disorders

    Medlock Holmes is called to investigate a series of extraordinary reports. One witness describes colours that seem alive. Another believes time has stopped. A third feels completely detached from their own body, while another speaks of overwhelming love, profound spiritual insight, or terrifying paranoia. Some recover within hours, while others continue to experience disturbing visual phenomena months or even years later. At first glance, every case appears to point towards severe mental illness. Yet Holmes notices an important clue. These experiences all follow exposure to substances capable of profoundly altering consciousness. This chapter explores the fascinating and rapidly evolving world of hallucinogen-related disorders. Unlike many other psychoactive substances, hallucinogens primarily alter perception, awareness, emotion, and the sense of self while often leaving consciousness intact. Rather than simply causing intoxication, they reshape how reality itself is experienced. Holmes discovers that “hallucinogen” is actually an umbrella term covering remarkably different substances. Classic psychedelics such as LSD, psilocybin, mescaline and DMT primarily act through serotonin receptors and produce vivid perceptual changes and altered states of consciousness. Dissociative agents such as ketamine and PCP disrupt the normal integration of sensory information, creating feelings of detachment from the body and environment. MDMA occupies another category altogether, enhancing emotional connectedness and empathy while also carrying significant medical risks. Other naturally occurring compounds, including salvinorin A and ibogaine, produce unique alterations of consciousness through entirely different neurochemical pathways. As Holmes interviews each individual, he realises that the same substance can produce vastly different experiences depending on the person, their expectations, and the environment in which it is taken. The concepts of “set” and “setting” emerge as critical determinants of whether the experience becomes therapeutic, frightening, enlightening, or dangerous. Most episodes resolve without lasting harm, but some do not. Holmes encounters individuals overwhelmed by panic during intoxication, others developing prolonged psychotic symptoms, and some experiencing persistent visual disturbances long after the drug has left their body. Hallucinogen Persisting Perception Disorder (HPPD) reminds him that, for a small number of people, altered perception can continue long after the original experience has ended, creating significant distress despite intact insight. The chapter also explores one of psychiatry’s most intriguing paradoxes. For decades these substances were viewed almost exclusively as drugs of misuse. Today, carefully controlled clinical research is once again investigating psychedelic-assisted therapies for treatment-resistant depression, post-traumatic stress disorder, addiction, and end-of-life distress. Ketamine has already become an established treatment for resistant depression, while other compounds continue to be evaluated in rigorous clinical trials. Holmes recognises that this changing landscape creates new responsibilities for clinicians. Patients may increasingly ask about psychedelic therapies, experiment with self-treatment, or present with complications of recreational use. Understanding both the potential benefits and the risks becomes essential. By the conclusion of the investigation, Holmes reaches a balanced perspective. Hallucinogens are neither miracle medicines nor simply dangerous drugs. They are powerful tools capable of profoundly altering consciousness. Used in uncontrolled settings, they may produce medical emergencies, psychological trauma, or persistent psychiatric disorders. Used carefully within structured therapeutic environments, they may eventually transform aspects of psychiatric treatment. The challenge for modern psychiatry is to approach these substances with curiosity, scientific rigour, and clinical caution-avoiding both fear and uncritical enthusiasm. Key Takeaways * Hallucinogens alter perception, consciousness, emotion, and sense of self without typically causing delirium. * Major classes include classic psychedelics, dissociatives, entactogens, and several naturally occurring compounds. * Different hallucinogens act through different neurochemical mechanisms. * “Set” and “setting” strongly influence the psychological experience. * Acute intoxication may present with anxiety, panic, perceptual distortions, paranoia, or psychosis. * PCP and ketamine are more likely to produce severe behavioural disturbance and medical complications. * Hallucinogen Persisting Perception Disorder (HPPD) causes recurrent perceptual disturbances after drug use. * Hallucinogen-induced psychosis may occur, particularly in vulnerable individuals. * Management focuses on supportive care, reassurance, benzodiazepines when required, and treatment of medical complications. * Ketamine is now established in psychiatric treatment, while psilocybin and MDMA continue to be investigated for therapeutic use. * Clinicians should distinguish substance-induced disorders from primary psychiatric illnesses. * Understanding both the risks and therapeutic potential of psychedelics is becoming increasingly important for modern psychiatric practice. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe

See All (658)

Trailer

About

Clinical Deep Dives is a Medlock Holmes podcast for clinicians and learners who want understanding, not just information. Using classic medical and surgical texts as a guide and the generative power of AI, each episode explores ideas with curiosity and clarity, designed for learning on the move and knowledge that actually sticks. drmanaankarray.substack.com

Information

  • Creator
    Med School Audio - Medical Knowledge Reimagined & Learning Made Memorable.
  • Years Active
    2026
  • Episodes
    658
  • Rating
    Clean
  • Copyright
    © Dr Manaan Kar Ray
  • Show Website
    Clinical Deep Dives